Newsweek on MSN1h
Amgen Drug Delivers More Weight Loss Than Competitors
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
Why Amgen's Weight Loss Result Is a Win for Eli Lilly
Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...
Amgen’s stock may see worst day in 24 years as weight-loss-drug data underwhelms
Amgen Inc.’s stock was down 7% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed ...
Amgen’s MariTide shows up to 20% average weight loss in Phase 2 study
Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart ...
Amgen's Phase 2 Results Were Not Bad, Don't Let Mr. Market Fool You
Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.
Amgen’s Stock Outlook: Balancing Maritide’s Weight Loss Data Concerns and Diabetes Treatment Potential
Analyst Mohit Bansal of Wells Fargo maintained a Hold rating on Amgen (AMGN – Research Report), retaining the price target of $335.00.Don't ...
What's Next for Amgen Obesity Drug After Investors Disappointed by Results
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
Hold Rating on Amgen’s Maritide Amid Uncertainties in Efficacy and Tolerability
Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Amgen (AMGN – Research Report). The associated price target ...
pharmaphorum10h
Amgen's big reveal of obesity data falls a little flat
That increased convenience will have to be accompanied by weight loss that is at least as effective as its rivals, and Amgen ...
Amgen stock sinks as weightloss drug fails to impress
Wall Street analysts did not think the data showed enough differentiation.